Phase 3 Clinical Trials With Primary Completion Dates in July 2018

This is a list of Phase 3 trials with primary completion dates in July 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AMRN Amarin Corporation plc 2018-07-01 Phase 3 NCT01492361 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
ANIK Anika Therapeutics Inc. 2018-07-01 Phase 3 NCT03390036 Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up
EDGE Edge Therapeutics, Inc. 2018-07-01 Phase 3 NCT02790632 Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
GRFS Grifols, S.A. 2018-07-01 Phase 3 NCT02796937 Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
MESO Mesoblast Limited 2018-07-01 Phase 3 NCT00482092 Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
RDHL Redhill Biopharma Ltd. 2018-07-01 Phase 3 NCT03198507 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
REPH Recro Pharma, Inc. 2018-07-01 Phase 3 NCT03323385 Evaluation of Preoperative N1539 in Colorectal Surgery
UTHR United Therapeutics Corporation 2018-07-01 Phase 3 NCT01560624 Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial Hypertension